- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
-
Endocrine Care
Pandzic Jaksic V, Majic A, Rezic T, Andric J, Jaksic O, Zrilic A, Marusic S
Primary Hyperparathyroidism Detected by Parathyroid Incidentaloma: Clinical Features, Work-up and ManagementActa Endo (Buc) 2021 17(2): 219-225 doi: 10.4183/aeb.2021.219
AbstractContext. With the widespread use of neck ultrasound, parathyroid incidentaloma (PI) emerges as an additional opportunity for incidental detection of primary hyperparathyroidism (PHPT). Objective and design. This study aimed to investigate PHPT cases detected by PI and to compare them with other PHPT patients. A retrospective analysis of newly diagnosed PHPT patients between 2014 and 2020 was conducted in our hospital. Subjects and methods. The cohort of 124 subjects was divided in two groups: 22 (17.7%) PHPT patients detected by PI (PI PHPT group) and the rest of 102 PHPT patients (non-PI PHPT group). Overall, 21 PIs were discovered on ultrasound and one was found during thyroid surgery. Clinical features, work-up and management of two study groups were compared. Results. The PI PHPT group had lower ionized calcium at diagnosis (p=0.034), lower peak serum calcium during follow-up (p<0.01), less fractures (p=0.022) and was less likely to meet the international criteria for parathyroidectomy (p<0.01). Positive sestamibi scan (p=0.022) and confirmed concordant localization in at least two different parathyroid imaging techniques (p=0.033) were more likely in the PI PHPT group. The frequency of surgical management did not differ between groups. Conclusions. PHPT detected by PI is clinically relevant and mostly comparable to PHPT in other patients with some features that correspond more often to a mild disease. Higher rate of positive preoperative localization in PHPT detected by PI might encourage parathyroidectomy even without the international criteria met. -
Case Report
Branisteanu DD, Galesanu C, Saviuc E, Lisnic N, Negru D, Bostaca T, Galesanu MR
One case of sellar and suprasellar chordomaActa Endo (Buc) 2005 1(2): 219-226 doi: 10.4183/aeb.2005.219
Abstract ReferencesWe describe one case of sellar and suprasellar chordoma found in a 44 year old female, with bitemporal hemianopsia and secondary amenorrhea, submitted to transfrontal surgery and telecobaltotherapy. Chordomas are slow growing neoplasms arising from notochordal remnants of the axial skeleton. The second most common site for chordomas, after the sacrococcygeal region, is the base of the skull. Skull base chordomas commonly result in cranial nerve deficits, such as blurred vision, facial weakness and swallowing difficulty. Occasionally, chordomas localized in the hypothalamic or pituitary region may lead to pituitary stalk disjunction, pituitary insufficiency and diabetes insipidus. Studies show that early diagnosis, combined with aggressive surgical resection, offers the best chance for long-term survival. Although optimal treatment consists of wide excision with adjuvant radiotherapy, skull base chordomas are rarely amenable to complete surgical removal. Traditionally, postoperative irradiation is delivered to doses of 6000-6500 cGy; however this approach controls the chordoma only for a few years. Prognosis depends on the histological grade of the tumor, atypical chordomas showing the lowest survival rate.1. Watkins L, Khudados ES, Kaleoglu M, Revesz T, Sacares P, Crockard HA. Skull base chordomas: a review of 38 patients, 1958-88. Br J Neurosurg 1993; 7(3):241-248. [CrossRef]2. Schechter MM, Liebeskind AL, Azar-Kia B. Intracranial chordomas. Neuroradiology 1974; 8(2):67-82. [CrossRef]3. Haridas A, Ansari S, Afshar F. Chordoma presenting as pseudoprolactinoma. Br J Neurosurg 2003; 17(3):260-262. [CrossRef]4. Kakuno Y, Yamada T, Hirano H, Mori H, Narabayashi I. Chordoma in the sella turcica. Neurol Med Chir (Tokyo) 2002; 42(7):305-308. [CrossRef]5. Thodou E, Kontogeorgos G, Scheithauer BW, Lekka I, Tzanis S, Mariatos P, Laws ER Jr. Intrasellar chordomas mimicking pituitary adenoma. J Neurosurg 2000; 92(6):976-982. [CrossRef]6. Lee HJ, Kalnin AJ, Holodny AI, Schulder M, Grigorian A, Sharer LR. Hemorrhagic chondroid chordoma mimicking pituitary apoplexy. Neuroradiology 1998; 40(11):720-723. [CrossRef]7. Kikuchi K, Watanabe K. Huge sellar chordoma: CT demonstration. Comput Med Imaging Graph 1994; 18(5):385-390. [CrossRef]8. Pinzer T, Tellkamp H, Schaps P. Intracranial chordoma. Case report of a destructively growing chondroid chordoma in the area of the sella turcica. Zentralbl Neurochir 1993; 54(3):133-138.9. Kagawa T, Takamura M, Moritake K, Tsutsumi A, Yamasaki T. A case of sellar chordoma mimicking a non-functioning pituitary adenoma with survival of more than 10 years. Noshuyo Byori 1993; 10(2):103-106.10. de Cremoux P, Turpin G, Hamon P, de Gennes JL. Intrasellar chordoma. Sem Hop 1980 18-25; 56(43-44):1769-1773.11. Johnsen DE, Woodruff WW, Allen IS, Cera PJ, Funkhouser GR, Coleman LL. MR imaging of the sellar and juxtasellar regions. Radiographics 1991; 11(5):727-758.12. Kachhara R, Nair S, Gupta AK, Radhakrishnan VV, Bhattacharya RN. Infrasellar craniopharyngioma mimicking a clival chordoma: a case report. Neurol India 2002; 50(2):198-200.13. Wanibuchi M, Uede T, Ishiguro M, Tatewaki K, Kurokawa Y, Yoshida Y. A case of suprasellar intradural chordoma. No Shinkei Geka 1994; 22(3):269-272.14. Couldwell WT, Weiss MH, Rabb C, Liu JK, Apfelbaum RI, Fukushima T. Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurge [CrossRef]15. Wang RZ, Ren ZY, Su CB, Yang Y, Tao W, Ma WB, Yin J. Extended transsphenoidal approach to giant tumors in sellar and clival area. Zhonghua Yi Xue Za Zhi 2004; 84(20):1693-1697.16. Zhang YZ, Wang CC, Gao XH, Liu PN, He Y, Piao MX. Clinical application of minimally invasive neuroendoscopic techniques. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27(1):22-25.17. Krishnan S, Foote RL, Brown PD, Pollock BE, Link MJ, Garces YI. Radiosurgery for cranial base chordomas and chondrosarcomas. Neurosurgery 2005; 56(4):777-784 [CrossRef]18. Radner H, Katenkamp D, Reifenberger G, Deckert M, Pietsch T, Wiestler OD. New developments in the pathology of skull base tumors. Virchows Arch 2001; 438(4):321-335. [CrossRef]19. Kakuno Y, Yamada T, Hirano H, Mori H, Narabayashi I. Chordoma in the sella turcica. Neurol Med Chir (Tokyo) 2002; 42(7):305-308. [CrossRef]20. Krengli M, Liebsch NJ, Hug EB, Orecchia R. Review of current protocols for protontherapy in USA. Tumori 1998; 84):209-216.21. Sims E, Doughty D, Macaulay E, Royle N, Wraith C, Darlison R, Plowman PN. Stereotactically delivered cranial radiation therapy: a ten-year experience of linac-based radiosurgery in the UK. Clin Oncol (R Coll Radiol) 1999; 11(5):303-320. [CrossRef] -
Endocrine Care
Orasan R, Awon R, Racasan S, Patiu IM, Samasca G, Kacso IM, Gherman Caprioara M
Effects of L-Carnitine on Endothelial Dysfunction, Visfatin, Oxidative Sterss, Inflammation and Anemia in Hemodialysis PatientsActa Endo (Buc) 2011 7(2): 219-228 doi: 10.4183/aeb.2011.219
AbstractBackground Supplementation of Lcarnitine is associated with improvement in some abnormalities present in hemodialysis (HD) patients. Objective. The study aim was to analyze the effect of oral L-carnitine supplementation on endothelial dysfunction (ED), oxidative stress (OS), inflammation and anemia in HD patients. Design. A prospective, longitudinal and observational study was performed in a single dialysis unit. Subjects and methods.We studied 31 HD patients: 21 patients formed the Lcarnitine supplementation group (group 1) and 10 entered the control group (group 2). At baseline and after 3 months of L-carnitine supplementation (500mg/day) we determined endothelial-dependent flow-mediated vasodilatation (FMD) and nitroglycerin induced endothelium independent vasodilatation, involving ultrasonographic brachial artery measurements, serum visfatin, malondialdehyde, body mass index, systolic blood pressure, diastolic blood pressure, interdialytic body weight gain, C-reactive protein, albumin, cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ferritin, transferrin saturation, hemoglobin, erythropoietin dose, calcium (Ca), phosphorus (P), parathormone and Kt/V . Results. In group 1, FMD (8.9 (4.5-12.5) to 10.6 (6.7-18), p=0.04) and Ca (8.4±0.6 to 8.8±0.5 mg/dL, p<0.001) significantly increased after L-carnitine supplementation, while visfatin (1.0 (0.2-1.3) to 0.4 (0-0.9) pg/mL, p=0.03), malondialdehyde (2.8 (2.4- 3.2) to 1.3 (1.2-1.5) nmol/mL, p<0.001) and P (5.6±1.3 to 5.0±1.2 mg/dL, p=0.005) significantly decreased. Albumin increased significantly in both groups (3.9±0.3 to 4.2±0.3 mg/dL, p<0.001 in group 1 and 3.7±0.3 to 4.0±0.3 mg/dL, p=0.02 in group 2). There were no other significant variations of the studied parameters. Conclusions. L-carnitine supplementation reduces ED, visfatin levels and markers of OS, but has no effect on inflammation, nutrition and anemia in HD patients. -
Endocrine Care
Galoiu S, Ioacara S., Baciu I. , Coculescu M
Reduced Life Expectancy in Women with Nonfunctioning Pituitary Adenomas and Concomitant HypopituitarismActa Endo (Buc) 2013 9(2): 219-228 doi: 10.4183/aeb.2013.219
AbstractAims. Earlier studies suggested that patients with nonfunctioning pituitary adenoma (NFPA) experience premature mortality, mostly from vascular diseases. The present study aims to identify risk factors associated with mortality in patients with NFPA. Methods. All consecutive patients admitted to a tertiary neuroendocrinology center for pituitary adenoma during 2001-2010 were screened. Only those with a final diagnostic of NFPA were retained. All 196 NFPA subjects (57.7% males, mean age 52.7±0.9 years) were followed-up for allcause mortality until December 31, 2011 (1298 person-years of follow-up). PAMCOMP software was used to calculate standardized mortality ratio (SMR), using the corresponding general population as reference. Cox regression analysis evaluated the independent hazards for mortality. Results. There were 26 deaths among 196 patients as compared to 20 expected. Standard Mortality Ratio (SMR) was 1.2 (95% Confidence interval (CI) 0.83-1.86). Females had a doubled mortality ratio: SMR 2.03 (95%CI 1.01-3.64), but males had a mortality ratio similar with general population: SMR 0.87 (95%CI 0.48-1.44). More patients with hypopituitarism for at least one axis deceased (22/156, 14.10%), as compared with patients without pituitary failure (1/22 patient deceased –2.07%), p=0.03. Prednison replacement for corticotrophin insufficiency (HR 1.46 (95%CI 1.12-1.90)) was correlated to mortality in females, but not in males, and mortality rose progressively with prednison dose (log rank: p=0.01). In males, last known maximal pituitary tumour diameter (HR 1.04 (95%CI 1.001-1.08) and age at baseline (HR 1.1 (95%CI 1.05-1.1) were modestly related to mortality. Conclusions. Females with nonfunctioning pituitary adenomas and hypopituitarism had a reduced life expectancy as compared with general population, possibly related to glucocorticoid substitution or a more severe pituitary insufficiency. -
Case Report
Celik M, Ayturk S, Celik H, Can N, Kucukarda A, Sezer A, Guldiken S, Tugrul A
A Rare Clinical Presentation: A Patient with Chronic Renal Failure, Secondary Hyperparathyroidism and CalciphylaxisActa Endo (Buc) 2016 12(2): 219-223 doi: 10.4183/aeb.2016.219
AbstractCalciphylaxis, also known as calcific uremic arteriolopathy (CUA), is usually observed in women and it is a serious complication of hyperparathyroidism secondary to chronic renal failure. CUA is characterized by ischemic tissue loss secondary to progressive vascular degeneration. Although it is rare, it may end up with sepsis and organ failure and can be fatal. Its pathogenesis is not fully understood, but it is thought that it occurs secondary to increased calcification activators such as oxidized LDL, TNF- α, calcitriol, fibronectin, collagen-I, and TGF-1α. The most effective treatment is managing underlying pathology and decreasing serum calcium and phosphorus levels. In this report, we aimed to present an end stage renal failure case with coexisting hyperparathyroidism, hyperthyroidism and calciphylaxis in whom cutaneous manifestations were healed 6 months after parathyroidectomy. -
Endocrine Care
Ji X, Shen L, Lin Z, Lv R
Comparative Growth Outcomes of Long-Acting and Short-Acting Growth Hormone Therapy in Pediatric Patients: A 12-Month Retrospective AnalysisActa Endo (Buc) 2025 21(2): 219-226 doi: 10.4183/aeb.2025.219
AbstractBackground. Growth hormone (GH) therapy is widely used for pediatric growth disorders, with short-acting (Saizen) and long-acting (Jintropin) formulations available. This study assesses height, weight, and bone age outcomes in children treated with Jintropin, Saizen, or a combination of both. Methods. This retrospective cohort study (N=108) compared Jintropin (n=31), Saizen (n=50), and Combination Therapy (n=27). To control for baseline heterogeneity (age, puberty) and repeated measures, analyses used ANCOVA and LMM. Post-hoc comparisons used Bonferroni correction. Safety was evaluated by ΔBA/ΔCA ratio. Results. Following multivariable LMM adjustment, the estimated marginal means for annualized GV were 9.30 cm/year (95% CI: 8.46–10.15) for Jintropin, 8.55 cm/year (95% CI: 7.90–9.20) for Saizen, and 9.56 cm/year (95% CI: 8.77–10.34) for Combination Therapy. Adjusted pairwise comparisons showed no significant efficacy differences between groups (Jintropin vs. Saizen: p=0.501; Combination vs. Saizen: p=0.160). Skeletal safety was confirmed across cohorts (ΔBA/ΔCA: 0.34, 0.46, 0.68), indicating no premature epiphyseal fusion. Conclusion. Long-acting Jintropin monotherapy provides growth outcomes comparable and non-inferior to daily Saizen, offering a convenient, effective alternative that reduces injection burden. The non-standard combination of long- and short-acting GH showed no statistically superior benefits, suggesting such complex regimens are unnecessary in clinical practice. -
Endocrine Care
Pricop C, Branisteanu D, Gatu A, Velicescu C, Ungureanu D, Mogos V, Serban L,, Serban DN
Particularities of Bone Metabolism and Calcium Regulators in a Group of Young Males with Idiopathic Hypercalciuria and Relapsing Kidney LithiasisActa Endo (Buc) 2014 10(2): 220-227 doi: 10.4183/aeb.2014.220
AbstractBackground. Idiopathic hypercalciuria is a risk factor for nephrolithiasis. Both renal stones and hypercalciuria are associated with lower bone mineral density (BMD), but the relationship between these modifications is not completely understood. Aims. To evaluate some metabolic particularities possibly related to relapsing nephrolithiasis (RN) in young male patients. Methods. We performed a crosssectional study including a group of 30 young male patients with RN and a group of 30 healthy, age and BMI (body mass index) matched controls (CTR). We evaluated calcium and phosphate metabolism, bone remodeling markers alkaline phosphatase (AP) and osteocalcin in serum and 24-hour urine samples, and lumbar and hip BMD. Results. We observed higher values of serum calcium (P<0.05) and 24 hour urinary calcium (P<0.001) in the RN group. Parathyroid hormone (PTH) and AP were also higher in the RN group (P<0.01), whereas serum 25OH-D3 was lower (P<0.01). BMD, T and Z scores were lower in the RN group in both the lumbar (P<0.01) and hip (P<0.05) regions. Conclusions. Young male patients with hypercalciuric RN have lower BMD and higher bone turnover. Higher PTH levels related to vitamin D deficiency may contribute to bone demineralization in certain cases. -
Case Report
Gafencu M, Bizerea TO, Stroescu RF, Costa R, Marginean O, Doros G
Thyroid Dysfunction in an AIDS PatientActa Endo (Buc) 2017 13(2): 220-223 doi: 10.4183/aeb.2017.220
AbstractObjective. Highly active antiretroviral therapy (HAART) is involved in the potential pathogenic mechanisms linking thyroid autoimmunity with immune restoration. The objective is to emphasize the emergence of autoimmune thyroid disease in a HIV patient long period after restoration of immune competence, unlinked to the immune reconstitution inflammatory syndrome (IRIS) occurring shortly after HAART initiation. We report a case of acute autoimmune thyroiditis with thyrotoxicosis in a patient with stage C3 HIV infection, who had been under HAART for more than 7 years. From the beginning there was a good immune response to the regimen, due to a good adherence and compliance (over 90%). Nine months after HAART initiation the viral load was undetectable (under 34 copies/μL) and the CD4 count reached 645 cells/mm3 (within normal range) after one year of treatment. Eight years after HAART initiation, based on clinical and laboratory findings, autoimmune thyroiditis was diagnosed. At this time immune competence with a normal CD4 count and a CD4/CD8 ratio over 1 was achieved. The chronic inflammation status of an HIV infection is the reason that autoimmunity appears outside the IRIS period. Treatment was initiated with antithyroid drugs. Thyroid function should be monitored periodically in HIV patients undergoing HAART. Future observations must be made for HIV related thyroid disorders using new classifications and studies with a larger number of patients. -
Endocrine Care
Kocak M, Akarsu E, Korkmaz H, Taysi S
The Effect of Antithyroid Drugs on Osteopontin and Oxidative Stress in Graves’ DiseaseActa Endo (Buc) 2019 15(2): 221-224 doi: 10.4183/aeb.2019.221
AbstractAbstract Objective. The aim of the present study is to evaluate the effects of methimazole (MTZ) and propylthiouracil (PTU) treatments on osteopontin (OPN) and oxidative stress in Graves’ disease (GD). Material and Methods. The study included 60 cases with GD in hyperthyroid state and taking no antithyroid treatment, and 30 healthy volunteers. GD patients were randomly separated into two groups; 30 of them took PTU, and the other 30 took MTZ treatments. Blood samples were taken from the patients with GD before the treatment, and three months after the treatment was begun, when they were in the euthyroid state; blood samples of the healthy control subjects were also taken at these times. Results. TAS and OSI levels before treatment were significantly higher in the GD group, when compared to the control group (p<0.001, for each). GD subjects taking PTU treatment had significantly higher TAS levels (p=0.001), and significantly lower TOS and OSI levels (p=0.008 and p=0.001, respectively). TAS levels significantly decreased in the patients taking MTZ treatment (p=0.029), but TOS and OSI levels did not change significantly (p>0.05). Pretreatment OPN levels were significantly higher in GD patients, when compared to the control group (p=0.014). OPN level significantly decreased in the GD group taking PTU treatment; however OPN levels in the group taking MTZ treatment did not change significantly when compared to the pretreatment value. Conclusion. PTU treatment is more effective in decreasing OPN and oxidative stress in GD patients, when compared to the MTZ treatment. -
Endocrine Care
Virgolici B, Popescu LA, Virgolici HM, Stefan CD, Mohora M, Timnea O
Effects of Omega-3 Fatty Acids Associated with Antioxidant Vitamins in Overweight and Obese ChildrenActa Endo (Buc) 2023 19(2): 221-227 doi: 10.4183/aeb.2023.221
AbstractIntroduction. Antioxidants and unsaturated fatty acids have protective effects in obesity. Aim. We investigated the benefits of Omega-3 fatty acids associated with antioxidant vitamins in obese children. Magnesemia and calcemia were observed in relation with other metabolic parameters, before and after the treatment. Materials and methods. 60 obese children were compared with 35 normal weight children. Each obese child received daily, one pill, containing: 130mg docosahexaenoic acid, 25mg of eicosapentaenoic acid, vitamin A 200μg, vitamin D 1,25μg, vitamin E 2,5mg and vitamin C 30mg for three months. All the participants were instructed not to change their lifestyle. Results. The serum values for these minerals and for 25(OH) vitamin D were lower in obese children. The obese children had insulin resistance (HOMA-IR) and an imbalance of serum adipocytokines. In obese children, the body mass index was negatively correlated with calcemia (r=-0.34) and serum 25(OH) vitamin D (r=-0.33). The HOMA-IR was negatively correlated with magnesemia (r=-0.34) and serum adiponectin (r=-0.29). The treatment improved the mineral serum level, the insulin sensitivity and the adipocytokines levels. Conclusion. In obese children, the intake of Omega-3 fatty acids associated with antioxidant vitamins, for three months improved calcemia and magnesemia and increased insulin sensitivity.